Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity

Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study

Zydus launches affordable Semaglutide in India after patent expiry

Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders

Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes

The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India

Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals

The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

DrStore partners with TatvaCare to revolutionize diabetes & metabolic care in India

Zydus and Torrent Pharma to co-market Semaglutide injection in India

Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device

Zydus, Lupin join forces to expand access to semaglutide in India

The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect

GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk